Non-ownership Filings
| FDA grants XF-73 Dermal QIPD for burn wound | Aug. 28, 2024 |
| Presentation at ESCMID on XF-73 Nasal Gel | Aug. 20, 2024 |
| Exploration of XF drug potential for CF | Aug. 14, 2024 |
| Last Day of Dealings on AIM | Aug. 12, 2024 |
| XF-73 prevents bacterial invasion of bloodstream | Aug. 05, 2024 |
| Result of GM and Cancellation of Trading on AIM | Jul. 31, 2024 |
| Treatment of XF-73 Nasal reduces antibiotic use | Jul. 22, 2024 |
Ownership Update Filings
| Director/PDMR Shareholding | Aug. 05, 2024 |
| Grant of Share Options | Oct. 20, 2023 |
| Director/PDMR Shareholding | Oct. 19, 2023 |
| Director/PDMR Shareholding | Oct. 04, 2023 |
| Director/PDMR Shareholding | May. 26, 2023 |
| Director Dealing | May. 26, 2023 |
| Grant of Share Options | May. 12, 2023 |